StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

Investment analysts at StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a report issued on Tuesday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Price Performance

Shares of CHEK opened at $2.27 on Tuesday. The firm has a 50 day simple moving average of $2.25 and a 200-day simple moving average of $2.58. Check-Cap has a 1-year low of $1.27 and a 1-year high of $4.63. The stock has a market cap of $13.28 million, a price-to-earnings ratio of -0.75 and a beta of 0.27.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.